Bayer says eye drug meets goal in diabetic macular edema trials
FRANKFURT Aug 6 (Reuters) - Bayer said on Tuesday that two late-stage studies testing its drug VEGF Trap-Eye against diabetic macular edema (DME) met their primary goals.
Bayer co-develops the eye drug, also known as Eylea, with Regeneron.
Bayer said that Regeneron now expects to submit an application for U.S. marketing approval for the treatment of DME in 2013, about a year earlier that previously planned.
- Tweet this
- Share this
- Digg this
- Polls say Scotland will spurn independence, but are they right?
- Ukraine accuses Russia of 'undisguised aggression' as rebels advance |
- UPDATE 1-Tennis-U.S. Open women's singles round 4 results
- Iceland cuts aviation alert to orange, no ash from new eruption |
- Australia unveils fresh sanctions against Russia over Ukraine